PipelineReview.com

Share

PipelineReview.com

 •  June 22

Phase 2 clinical trial data demonstrate that long-acting buprenorphine (CAM2038), a novel subcutaneous buprenorphine depot formulation, produces an immediate and sustained blockade of opioid effects and suppression of withdrawal symptoms in adults with opioid use disorder. Data from the Opioid Challenge Study were presented today at the annual...

PipelineReview.com

 •  May 24

KEYTRUDA Now Approved for Patients with MSI-H or Mismatch Repair Deficient Solid Tumors That Have Progressed Following Prior Treatment and Who Have No Satisfactory Alternative Treatment Options, Which Includes MSI-H or Mismatch Repair Deficient Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and...

PipelineReview.com

 •  February 2

Supplemental new drug application on track for second quarter 2017 filing WALTHAM, MA, USA I February 02, 2017 I AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced results from its definitive pharmacokinetic (PK) study designed to demonstrate comparable bioavailability of the subcutaneous auto-injector product and the current intramuscular...

PipelineReview.com

 •  April 23, 2016

Intravenous form of carbamazepine under FDA review for use in adults with certain seizure types who are unable to take their oral carbamazepine DEERFIELD, IL, USA I April 22, 2016 I Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for intravenous...

PipelineReview.com

 •  May 16, 2015

VENTURE-AF, the First Global, Prospective, Randomized Trial of Any Novel Oral Anticoagulant in this Setting, Presented as Late-Breaking Clinical Trial
RARITAN, NJ, USA I May 14, 2015 I Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced results from the VENTURE-AF trial. The study explored the potential of ...